Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Market Cap | Price | Price Target | Upside/Downside | Top Analysts Upside/Downside | Consensus | Top Analysts Consensus | Analysts | Top Analysts | Fore. Revenue Growth | Fore. Earnings Growth | Forecast ROE | Forecast ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARGX | ARGENX SE | $35.11B | $577.89 | $755.80 | 30.79% | Strong Buy | 10 | 980.58% | 26.50% | 41.02% | 36.36% | |||
| CRMD | CORMEDIX INC | $987.53M | $14.56 | $15.00 | 3.02% | Strong Buy | 4 | 57.11% | 114.45% | 184.78% | 141.92% | |||
| GYRE | GYRE THERAPEUTICS INC | $749.12M | $7.99 | N/A | N/A | N/A | N/A | 52.00% | 179.85% | 399.13% | 209.49% | |||
| TGTX | TG THERAPEUTICS INC | $5.72B | $36.01 | $55.00 | 52.74% | Buy | 1 | 35.46% | 108.03% | 225.80% | 81.59% | |||
| CORT | CORCEPT THERAPEUTICS INC | $7.43B | $70.06 | $142.00 | 102.68% | Strong Buy | 4 | 31.13% | 52.86% | 126.10% | 101.79% | |||
| RPRX | ROYALTY PHARMA PLC | $19.59B | $34.84 | N/A | N/A | N/A | N/A | 20.30% | 43.47% | 31.42% | 17.47% | |||
| VCEL | VERICEL CORP | $2.15B | $42.67 | $61.25 | 43.54% | Strong Buy | 4 | 25.79% | 196.11% | 35.10% | 24.43% | |||
| KRYS | KRYSTAL BIOTECH INC | $3.96B | $137.07 | $210.50 | 53.57% | Strong Buy | 6 | 34.23% | 36.35% | 34.84% | 31.93% | |||
| AUPH | AURINIA PHARMACEUTICALS INC | $1.11B | $8.18 | N/A | N/A | N/A | N/A | 17.88% | 64.08% | 76.77% | 53.25% | |||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $1.89B | $32.97 | $55.17 | 67.32% | Strong Buy | 6 | 15.87% | 23.30% | 52.24% | 35.66% | |||
| HALO | HALOZYME THERAPEUTICS INC | $6.65B | $53.98 | $64.17 | 18.87% | Buy | 6 | 15.12% | 19.36% | 224.59% | 49.31% | |||
| CPRX | CATALYST PHARMACEUTICALS INC | $2.87B | $23.53 | $32.50 | 38.12% | Strong Buy | 4 | 10.42% | 16.72% | 40.85% | 35.70% | |||
| INCY | INCYTE CORP | $13.11B | $67.75 | $72.46 | 6.94% | Hold | 11 | 8.64% | 197.02% | 46.74% | 29.81% | |||
| ADMA | ADMA BIOLOGICS INC | $4.97B | $20.81 | $28.50 | 36.95% | Strong Buy | 2 | 19.85% | 13.93% | 108.68% | 79.49% | |||
| MNKD | MANNKIND CORP | $1.13B | $3.71 | $9.50 | 156.06% | Strong Buy | 2 | 14.03% | 40.95% | -212.58% | 30.38% | |||
| EXEL | EXELIXIS INC | $11.34B | $41.59 | $39.94 | -3.97% | Buy | 16 | 9.53% | 15.53% | 60.91% | 45.75% | |||
| NVO | NOVO NORDISK A S | $356.44B | $79.83 | $64.00 | -19.83% | Hold | 1 | 10.82% | 14.61% | 121.91% | 34.53% | |||
| MDXG | MIMEDX GROUP INC | $892.12M | $6.04 | $13.00 | 115.23% | Strong Buy | 1 | 11.95% | 35.86% | N/A | N/A | |||
| TECH | BIO-TECHNE CORP | $7.92B | $50.52 | $72.00 | 42.52% | Buy | 10 | 3.89% | 50.63% | 17.01% | 12.98% | |||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $6.69B | $108.50 | $183.08 | 68.74% | Strong Buy | 12 | 5.80% | 48.52% | N/A | N/A | |||
| VCYT | VERACYTE INC | $2.07B | $26.44 | $42.00 | 58.85% | Strong Buy | 5 | 8.13% | 49.36% | 7.47% | 6.79% | |||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $10.78B | $56.22 | $95.78 | 70.36% | Strong Buy | 9 | 9.05% | 23.96% | N/A | N/A | |||
| NAGE | NIAGEN BIOSCIENCE INC | $1.07B | $13.63 | $14.53 | 6.57% | Strong Buy | 4 | 18.38% | 8.02% | 40.56% | 27.60% | |||
| GMAB | GENMAB A | $15.11B | $22.82 | $36.33 | 59.22% | Strong Buy | 3 | 16.71% | 11.83% | 3.91% | 3.14% | |||
| ACAD | ACADIA PHARMACEUTICALS INC | $3.63B | $21.71 | $26.71 | 23.05% | Buy | 14 | 9.51% | 2.12% | 50.41% | 34.07% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.